A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Ass… (NCT03743064) | Clinical Trial Compass
CompletedPhase 3
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
United States, Australia, Belgium318 participantsStarted 2019-05-06
Plain-language summary
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia (cancer-related weight loss). The main question it aimed to answer was as follows: Do patients who receive anamorelin HCl gain more body weight and show more improvement in anorexia symptoms than those who receive placebo.
Approximately 316 patients were to be enrolled in the study. Of these patients, an equal number were to be assigned to each treatment group (anamorelin HCl or placebo). Participants were to take their assigned study drug by mouth once daily for a total of 24 weeks. During this treatment period, the patients were to visit the clinical study site every 3 weeks for health and other study-related assessments. Two weeks after the last treatment, patients were to receive a follow-up phone call.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Signed written informed consent
. Female or male ≥18 years of age
. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease
. Body mass index \< 20 kg/m2 with involuntary weight loss of \>2% within 6 months prior to screening
. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS
. Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this was a Phase 3 trial specifically studying anamorelin for weight loss and appetite problems in advanced non-small cell lung cancer, can you tell me whether the results showed meaningful improvements in body weight and appetite symptoms, and whether those improvements were considered clinically significant for patients like me?
2This trial measured changes over 12 weeks — would committing to that kind of treatment schedule and monitoring be realistic given everything else I'm managing with my NSCLC treatment, and how does that timeline fit with my overall care plan?
3Since the trial is now completed, is anamorelin approved or available outside of a clinical trial, or would I need to look into a compassionate use or expanded access program to potentially access it?
4Cachexia and appetite loss can sometimes be addressed with existing supportive care options — how does anamorelin compare to what's already available to me, and should we try standard approaches first before considering a newer drug from this study?
5Given that I have advanced NSCLC, how would you weigh the potential benefit of treating my weight loss and anorexia with something like anamorelin against focusing our energy on the cancer treatment itself?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean Change From Baseline in Body Weight Over 12 Weeks
Timeframe: Mean change from baseline over 12 weeks.
2
Mean Change From Baseline in 5-item Anorexia Symptom Subscale (5-IASS) Over 12 Weeks
Timeframe: Mean change from baseline over 12 weeks.
. Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
. Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
Exclusion criteria
. Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)
. Woman who is pregnant or breast-feeding
. Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:
. NCI CTCAE Grade 3 or 4 oral mucositis,
. NCI CTCAE Grade 3 or 4 GI disorders \[nausea, vomiting, diarrhea, and constipation\],
. mechanical obstructions making patient unable to eat, or
. severe depression
. Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period